Chronic myeloid leukemia management during pregnancy: a case report

Article Sidebar

PDF
Published: Jun 11, 2022
DOI: https://doi.org/10.52600/2763-583X.bjcr.2022.2.3.47-53
Keywords:
Pregnancy, Chronic Myeloid Leukemia, Management

Main Article Content

Luina Benevides Lima
Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará
https://orcid.org/0000-0001-6503-8657
Caroline de Fátima Aquino Moreira-Nunes
Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará
https://orcid.org/0000-0001-5845-3481
Felipe Pantoja Mesquita
Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará
Lais Lacerda Brasil de Oliveira
Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará
https://orcid.org/0000-0003-2814-3575
Emanuel Cintra Austregésilo Bezerra
Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará
Emerson Lucena da Silva
Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará
https://orcid.org/0000-0002-5761-8413
Fernando Barroso Duarte
Department of Haematology, Walter Cantidio University Hospital, Federal University of Ceará
Acy Telles de Souza Quixadá
Department of Haematology, Walter Cantidio University Hospital, Federal University of Ceará
https://orcid.org/0000-0002-2146-7123
Maria Elisabete Amaral de Moraes
Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará
Raquel Carvalho Montenegro
Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará
https://orcid.org/0000-0002-3861-293X

Abstract

Chronic Myeloid Leukemia (CML) is characterized by the increased and unregulated growth of myeloid cells in bone marrow and accumulation of these cells in blood. Its occurrence during pregnancy is a very rare condition and the correct management is not well stablished yet. We present a case of a 21-year-old female diagnosed with CML during pregnancy. The protocol chose by the doctor was hydroxyurea on second trimester, and interferon-alpha on third trimester. The baby was born healthy and at the expected time. After giving birth, the patient started Imatinib Mesilate (IM) 400mg/day treatment and was able to control the disease.

Article Details

How to Cite
Lima, L. B., Moreira-Nunes, C. de F. A., Mesquita, F. P. ., de Oliveira, L. L. B., Bezerra, E. C. A. ., da Silva, E. L. ., Duarte, F. B. ., Quixadá, A. T. de S., de Moraes, M. E. A., & Montenegro, R. C. (2022). Chronic myeloid leukemia management during pregnancy: a case report. Brazilian Journal of Case Reports, 2(3), 47–53. https://doi.org/10.52600/2763-583X.bjcr.2022.2.3.47-53
Issue
Vol. 2 No. 3 (2022): July/September - 2022
Section
Clinical Case Reports
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Author Biographies

Luina Benevides Lima, Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará

Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará, Ceara, CE, Brazil.

Caroline de Fátima Aquino Moreira-Nunes, Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará

Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, Ceara, CE, Brazil.

Felipe Pantoja Mesquita, Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará

Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará, Ceara, CE, Brazil.

Lais Lacerda Brasil de Oliveira, Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará

Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará, Ceara, CE, Brazil.

Emanuel Cintra Austregésilo Bezerra, Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará

Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará, Ceara, CE, Brazil.

Emerson Lucena da Silva, Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará

Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará, Ceara, CE, Brazil.

Fernando Barroso Duarte, Department of Haematology, Walter Cantidio University Hospital, Federal University of Ceará

Department of Haematology, Walter Cantidio University Hospital, Federal University of Ceará, Ceará, CE, Brazil.

Acy Telles de Souza Quixadá, Department of Haematology, Walter Cantidio University Hospital, Federal University of Ceará

Department of Haematology, Walter Cantidio University Hospital, Federal University of Ceará, Ceará, CE, Brazil.

Maria Elisabete Amaral de Moraes, Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará

Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará, Ceara, CE, Brazil.

Raquel Carvalho Montenegro, Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará

Laboratory of Pharmacogenetics, Drug Research and Development Center (NPDM), Federal University of Ceará, Ceara, CE, Brazil.

References

Palani R, Milojkovic D, Apperley JF. Managing pregnancy in chronic myeloid leukaemia. In: Hehlmann R. (eds) Chronic Myeloid Leukemia. Hematologic Malignancies. Springer, Cham.

Berman E. Pregnancy in patients with Chronic Myeloid Leukemia. Journal of the National Comprehensive Cancer Network, 2018. 16 (5S).

Law AD, Kim DDH, Lipton JH. Pregnancy: part of life in Chronic Myelogenous Leukemia. Leukemia & Lymphoma, 2017. 58(2):280-287.

Pallavee P, Samal R, Ghose S. Chronic myeloid leukaemia in pregnancy: call for guidelines. Journal of Obstetrics and Gynaecology, 2019. 39(4): 582-583.

Bhandari A, Rolen K, Shah BK. Management of Chronic Myelogenous Leukemia in pregnancy. Anticancer research, 2015. 35: 1-11.

Salem W, Kailiang L, Krapp C, Ingles SQ, Bartolomei MS, Chung K, Paulson RJ, Nowak RA, McGinnis LK. Imatinib treatments have longterm impact on placentation and embryo survival. Scientific Reports, 2019; 9: 2535.

Moura AC, Delamain MT, Duarte GBO, Lorand-Metze I, Souza CA, Pagnano KBB. Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center. Hematol transfus cell ther, 2019. 41(2): 125–128.

Sossela FR, Zoppas BCA, Weber LP. Chronic Myeloid Leukemia: clinical aspects, diagnosis and main changes observed in complete blood count. Revista Brasileira de Análises Clínicas, 2017. 49(2): 127-130.

Mahmoud HK, Samra MA, Fathy GM. Hematologic malignancies during pregnancy: a review. Journal of Advanced Research, 2016. 7: 589–596.

Sheng W, Sun N. Successful pregnancy and delivery in a patient with chronic myeloid leukemia: a case report and review of the literature. Sheng and Sun SpringerPlus, 2016. 5 (1): 2055.

Hepner A, Negrini D, Hase EA, Exman P, Testa L, Trinconi AF, Filassi J R, Francisco RPV, Zugaib M, O’Connor TL, Martin MG. Cancer During Pregnancy: The Oncologist Overview. World J Oncology, 2019. 10(1): 28-34.

Mikhael S, Pascoe A, Prezzato J. Recurrence of Chronic Myeloid Leukemia during Pregnancy Subsequently Achieving Complete Medical Remission. Case Reports in Oncological Medicine, 2017.

Martin J, Ramesh A, Devadasan L, Palaniappan Martin JJ. An uneventful pregnancy and delivery, in a case with chronic myeloid leukemia on imatinib. Indian Journal of Medical and Paediatric Oncology, 2011. 32 (2): 109–111.

Sahu KK, Dhibar DP, Varma S, Malhotra P. CML with pregnancy: real challenges in developing nations. Leukemia & Lymphoma, 2017. 58(6): 1518-1519.

Maia Filho PA, Pereira JF, Almeida Filho TP, Cavalcanti BC, Sousa JC, Lemes RPG. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity. Environmental and Molecular Mutagenesis; 2018. 60 (3): 302-304.

Regan S, Yang X, Finnberg NK, El-Deiry WS, Pu JJ. Occurrence of acute myeloid leukemia in hydroxyurea-treated sickle cell disease patient, Cancer Biology & The-rapy, 2019. 20 (11): 1389-1397.

Ault P, Kantarjian H, O'Brien S, Faderl S, Beran M, Rios MB, Koller C, Giles F, Keating M, Talpaz M, Cortes J. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006 Mar 1;24(7):1204-8. doi: 10.1200/JCO.2005.04.6557.

Most read articles by the same author(s)